GB2431581A - Ozonated oil formulations - Google Patents
Ozonated oil formulations Download PDFInfo
- Publication number
- GB2431581A GB2431581A GB0621173A GB0621173A GB2431581A GB 2431581 A GB2431581 A GB 2431581A GB 0621173 A GB0621173 A GB 0621173A GB 0621173 A GB0621173 A GB 0621173A GB 2431581 A GB2431581 A GB 2431581A
- Authority
- GB
- United Kingdom
- Prior art keywords
- oil
- ozonated
- compounds
- skin
- ozone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000009472 formulation Methods 0.000 title claims abstract description 24
- 239000003921 oil Substances 0.000 claims abstract description 74
- 235000019198 oils Nutrition 0.000 claims abstract description 74
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 206010000496 acne Diseases 0.000 claims abstract description 17
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 16
- 235000021302 avocado oil Nutrition 0.000 claims abstract description 12
- 239000008163 avocado oil Substances 0.000 claims abstract description 12
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 8
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 7
- 230000001815 facial effect Effects 0.000 claims abstract description 7
- 239000007934 lip balm Substances 0.000 claims abstract description 7
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 6
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 5
- 201000000849 skin cancer Diseases 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 4
- 210000003491 skin Anatomy 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 210000002615 epidermis Anatomy 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 210000004207 dermis Anatomy 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 3
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 3
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 210000001723 extracellular space Anatomy 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000006385 ozonation reaction Methods 0.000 description 11
- 230000035876 healing Effects 0.000 description 8
- 206010033733 Papule Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 241001635598 Enicostema Species 0.000 description 4
- 206010027626 Milia Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 3
- -1 IL-I Proteins 0.000 description 3
- 206010054107 Nodule Diseases 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229930002875 chlorophyll Natural products 0.000 description 3
- 235000019804 chlorophyll Nutrition 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010000591 Acrochordon Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000001348 Chloracne Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012426 Dermal cyst Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 206010014201 Eczema nummular Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010305 Epidermal Cyst Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 206010066295 Keratosis pilaris Diseases 0.000 description 1
- 208000004204 Larva Migrans Diseases 0.000 description 1
- 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 208000025618 Paget disease of nipple Diseases 0.000 description 1
- 208000024024 Paget disease of the nipple Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039251 Rubber sensitivity Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000001924 Tungiasis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001532 anti-fungicidal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003071 aquagenic pruritus Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000013046 dyshidrosis Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000005391 latex allergy Diseases 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 206010035114 pityriasis rosea Diseases 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 201000011414 pompholyx Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- YJVLWFXZVBOFRZ-UHFFFAOYSA-N titanium zinc Chemical compound [Ti].[Zn] YJVLWFXZVBOFRZ-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutically or cosmetically acceptable oil that has been ozonated with an amount of ozone less than the amount required to saturate the oil is disclosed.The oil may be used as a cosmetic formulation, such as a lip balm, moisturiser, facial cleanser, anti-aging product or massage oil. Alternatively the composition may be used in the treatment or prophylaxis of a dermatological condition, such as acne, psoriasis, eczema or skin cancer, or a dematological condition associated with Type diabetes. In a preferred embodiment, the oil is avocado oil.
Description
<p>Ozonated oil formulations</p>
<p>Description</p>
<p>The present invention relates to ozonated oils. In particular, it relates to oils ozonated to different levels, to pharmaceutically or cosmetically acceptable formulations comprising these oils for topical application to the skin, and to various pharmaceutical and cosmetic uses of these oils.</p>
<p>Research in the dermatological field is ever-expanding, not least because the skin is the largest organ of the body and plays a wide range of important roles. Common skin diseases or conditions include eczema, acne, psoriasis, skin cancer, viral warts and uticaria. Whereas some skin disorders are isolated, others arc symptoms of internal disease, such as rheumatic disease. Topically administered treatments are widespread, ranging from simple zinc-and titanium-based emollients to soothe and hydrate the skin, to creams containing active agents like antibiotics to treat infections and steroids to treat inflammatory conditions such as eczema and psoriasis. However, orally administered agents have also been used, such as the retinoid isotrenitoin for severe forms of acne, and ultraviolet light has been employed to treat diseases such as mycosis fungoides.</p>
<p>There are a number of problems with the known treatments for skin disorders. For instance, many antibiotic creams are too powerful for long-term use, and serious side effects have been associated with steroid therapy, including skin atrophy and steroid allergy. Alternatives to these creams have thus been keenly sought in the art.</p>
<p>There has been some investigation into ozonated pharmaceutical formulations, most commonly olive oil based formulations, as ozone is known to have useful properties such as microbicidal activity. For instance, FR 2,784,388 discloses the pharmaceutical and cosmetic use of oils such as olive oil that have been ozonated to saturation. US 4,451, 480 discloses ozonized oils such as olive oil, jojoba oil and sesame oil for topical application to the skin for the treatment of acne, which have an active oxygen content of about 0.1 to about 15 % by weight of the ozonide component.</p>
<p>There have been problems associated with ozonated olive oil formulations, however. WO 2006/021924 notes that ozonated olive oil is unstable due to its chlorophyll content and the relatively high concentration of short chain fatty acids relative to long chain fatty acids. It discloses ozonated avocado oil for therapeutic and cosmetic use and a method of producing such an oil. It notes that avocado oil has a higher concentration of long chain fatty acids relative to short chain fatty acids, and in the invention the chlorophyll naturally present is removed before ozonation. Nevertheless, this document does not consider suitable ozonation levels of the oil nor correlate these with particular pharmaceutical uses.</p>
<p>For a number of reasons, ozonated formulations have been slow to gain widespread acceptance for pharmaceutical use. If the majority of the known ozonated oils are applied to the skin on a regular basis, their high ozone concentration causes overstimulation of cells, producing undesired effects such as irritation, rashes and even rapid flaking of the skin. In some cases, the strong smell of ozone is unpleasant and causes the eyes to water. Furthermore, others of the known oils have non-specific physiological effects that are hard to control.</p>
<p>In seeking to overcome one or more of the above-mentioned problems, a range of ozonated oils have been developed that may be tailored to particular therapeutic uses, and that have also been found to have advantageous properties in the cosmetic</p>
<p>field.</p>
<p>Accordingly, in a first aspect of the invention there is provided a pharmaceutically or cosmetically acceptable oil that has been ozonated with an amount of ozone less than the amount required to saturate the oil.</p>
<p>In a second aspect of the invention there is provided avocado oil ozonated with 1.0 -6.0 g of ozone per 100 g of oil.</p>
<p>In a third aspect of the invention there is provided ozonated avocado oil containing 1.0-6.0 % ozonated compounds.</p>
<p>In a fourth aspect of the invention there is provided a pharmaceutically or cosmetically acceptable formulation comprising an oil according to the invention in any of its first to third aspects, for topical application to the skin.</p>
<p>In a fifth aspect of the invention there is provided a lip balm, moisturiser, facial, cleanser or anti-aging product, or massage oil comprising a formulation according to the invention in its fourth aspect.</p>
<p>In a sixth aspect of the invention there is provided the use of a formulation according to the invention in its fourth aspect as a lip balm, moisturiser, facial, cleanser or anti-aging product, or as a massage oil.</p>
<p>In a seventh aspect of the invention there is provided an oil according to the invention in any of its first to third aspects for use in therapy.</p>
<p>In an eighth aspect of the invention there is provided the use of an oil according to the invention in any of its first to third aspects for the manufacture of a medicament for USC in the treatment or prophylaxis of a dermatological condition, disease or disorder.</p>
<p>Preferred embodiments of the invention are as set out below or as defined in the sub-claims.</p>
<p>Figure 1 illustrates various regions of the skin and underlying adipose tissue, and penetration of ozone and/or ozonides through these regions.</p>
<p>The oils of the present invention have one or more beneficial properties and may be used as pharmaceuticals, cosmetics or so-called "cosmeceuticals". For instance, they may be antibacterial, antiviral and/or antifungicidal. They exert a rapid and efficient sterilizing effect, produce an improvement and acceleration of skin and tissue healing and are efficient immunoactivators.</p>
<p>They n-lay stimulate blood circulation, improving the rheological properties oi red blood cells, activating red blood cell metabolism, shifting the Hb02/Hb balance to the right and improving the release of oxygen. They may cause an increase in adenosine triphosphate (ATP), an increase in 2,3 diphosphoglycerate (2,3 DGP) and a drop in glutathione (GSH).</p>
<p>io In imrnunocompetent cells, the inventive oils may activate nuclear factor NFkB, and cause an induction and release of cytokines such as IL-I, IL-2, IFN-y, TNF-a and TGF-13.</p>
<p>The oils used have a maximum amount of ozone that can be incorporated, either by reaction or otherwise. The oils of the invention are ozonated with an amount of ozone less than this maximum amount required to "saturate" the oil. They have been found to have fewer side effects than the known saturated oils, whilst still maintaining therapeutic efficacy. In particular, skin is made up of several layers, including the epidermis, papillary dermis and reticular dermis, as shown in Figure 1, and the oils of the invention have various levels of action within the skin cells, blood cells, sebaceous glands, nerve tissue, muscle tissue and skin pores. By varying the concentration of ozone or ozonated species in the oil, the depth of penetration through the skin and the effects at a cellular level can be controlled and specifically tailored according to its desired use.</p>
<p>The well known cold corona discharge method may be used to produce so-called medical grade ozone (typically a 0.05 -5 % mixture of 03 and 02) from medical grade oxygen. The oil is placed into a pressurised vat and the medical grade ozone can then be bubbled through until the desired ozonation level has been reached.</p>
<p>The method disclosed in WO 2006/021924 may be used. Where the exact composition of the oil is batch dependent, one can take a known quantity of oil, measure the time required to ozonate to saturation and then calculate the time required to ozonate to the desired concentration.</p>
<p>In this manner, ozone is "stabilized" and the ozonated oil has a relatively long shelf life, e.,g. nvclve months if stored at low temperatures.</p>
<p>In a preferred embodiment of the invention, the oil contains unsaturated compounds, i.e. compounds bearing carbon-carbon double bonds. Preferably, these compounds are unsaturated fatty acids.</p>
<p>The exact composition and mechanism of action is not fully understood. However, it is believed that when ozone gas is introduced, at least part of it may react to form compounds such as ozonides, aldehydes or lipoperoxides. The Criegee mechanism may be involved in these reactions. When applied to the skin, the ozonation products may pass through to the intercellular space of red blood cells and immunocompetent cells to influence cellular metabolism.</p>
<p>At least a part of thc ozone introduced into the oil may remain in associated but unreacted form, for example in sequestered form or as a clathrate. Alternatively or in addition to the mechanisms outlined above, after application to the skin the ozone may be released and may break down to form oxygen free radicals, which are highly reactive and damage or destroy foreign organisms. Concurrently, it may stimulate the production of enzymes in the cell wall of the body's own cells such as glutathione peroxidase, catalase and superoxide dismutase, thus enhancing the cell wall resistance to attack by ozone.</p>
<p>The most preferred oil for use in the present invention is avocado oil. Analysis shows that the oil contains essential vitamins, minerals and fatty acids that are good for skin nutrition. In addition, it contains a rare DNA component that stimulates the skin to regenerate its own natural collagen (which provides skin elasticity).</p>
<p>Unlike other plant oils, it has a high natural concentration of antioxidants such as vitamin E, which are absorbed through the dermal layers and are known to combat aging of living cells. It is suspected that ozonation gives rise to a synergistic effect at a cellular level with the vitamin E naturally present, since vitamin E stabilizes the structure of the biomembrane by scavenging free radicals, protecting against the generation of damaging lipoperoxides in the biomembrane.</p>
<p>Where the oil to be ozonated contains chlorophyll, this can optionally be removed before ozonation.</p>
<p>The oil of the invention may be useful in the treatment or prevention of a variety of different dermatological conditions, diseases or disorders, including acne, actinic keratosis, angioma, aquagenic pruritus, athlete's foot, atopic dermatitis, baldness, basal cell carcinoma, bed sores, Behcet's disease, blepharitis, Bowen's disease, bullous pemphigoid, canker sores, carbuncles, cellulitis, chloracne, dyshidrosis, cold sores, creeping eruption, dermatitis, dermatitis herpetiformis, dermatofibroma, diaper rash, eczema, epidermolysis bullosa, erysipelas, erythroderma, genital warts, hidradenitis suppurativa, hives, hyperhidrosis, ichthyosis, impetigo, Kaposi's sarcoma, keloid, keratoacanthoma, keratosis pilaris, lichen planus, lichen simplex chronicus, lipoma, lymphadenitis, malignant melanoma, melasma, miliaria, molluscum contagiosum, nummular dermatitis, Paget's disease of the nipple, pediculosis, pemphigus, perioral dermatitis, photoallergy, pityriasis rosea, pityriasis rubra pilaris, psoriasis, Raynaud's disease, ring worm, rosacea, scabies, scieroderma, sebaceous cyst, seborrheic keratosis, seborrhoeic dermatitis, shingles, skin cancer, skin tags, spider veins, squamous cell carcinoma, stasis dermatitis, tick bites, tinea barbae, tinea capitis, tinea corporis, tinea cruris, tinea pedis, tinea unguium, tinea versicolor, tinea, tungiasis, vitiligo, or warts.</p>
<p>The formulation of the invention having an ozonation level of 1.0 -2.0 % is particularly suitable for use as a lip balm. It helps to prevent the lips from cracking and drying Out and is advantageously applied sparingly once to three times per day.</p>
<p>The low ozone concentration provides cellular granulation to the skin cells on the lips, allowing them to regenerate at an optimum rate thus accelerating healing time.</p>
<p>The formulation of the invention having an ozonation level of 2.0 -3.0 % is particularly suitable for use as a moisturiser. It is thought to primarily act on the epidermis, conditioning and brightening the complexion and regulating oil glands.</p>
<p>Angiogenesis promotes microcapillaries to increase blood circulation into the skin layers. The antioxidants such as vitamin E present in avocado oil also protect against environmental pollutants and free radicals generated by UV from the sun.</p>
<p>This formulation provides cellular granulation to the skin cells and neutralizes excess acids, balancing skin pH to a more alkaline level. It is preferably applied daily and to the face.</p>
<p>The formulation of the invention having an ozonation level of 3.0 -4.0 % is particularly suitable for use for facials, as a cleanser or as an anti-aging product. It is thought to primarily act on the epidermis and dermal layers, and provides an increased reaction process of repair and replication at a cellular level, cleaning the lymphatic channels around the face and providing antibacterial and viral protection against skin infection within the pores of the skin. This builds a much stronger layer of healthier skin cells, well before the cells mature, thereby lifting the tone and texture of the skin, providing soft smooth complexion with increased elasticity and delaying the aging process of the cells. Further, it cleanses sweat glands, neutralizes toxins and balances skin pH, reducing spots and pimples. It is preferably used once to three times per week, and stored in a dark and cool place out of direct sunlight.</p>
<p>The formulation of the invention having an ozonation level of 4.0 -5.0 % is particularly suitable for use as a massage oil, especially for sports massage. It is thought to act upon the epidermis, dermal layers, nerve and muscle tissue, conditioning the skin but also reducing aches and pains in muscles, reducing lactic acid build up and increasing ATP in the muscle cells. It aids healing of damaged muscles, ligaments and tendons, for instance in sports injuries, and can also be used to increase stamina in the muscles and reduce recovery periods after strenuous exercise or sports. It can be applied all over the body, or in specific areas such as to lymphatic zones to cleanse the lymphatic channels and lymph nodes and aid lymphatic circulation, and also to boost the immune system by increasing immunoproteins. It may be used every day, and is preferably stored in a cool dark place out of direct sunlight.</p>
<p>The formulation of the invention having an ozonation level of 5.0 -6.0 % is particularly suitable for use as a cosmeceutical or pharmaceutical. It penetrates deeply through the skin and can be used to treat a whole range of dermatological conditions including a wide spectrum of acne, cold sores and spots. It has a strongly sterilizing and cleansing effect, conditioning the skin to deal with most types of acne and spots. It can also be used to treat other skin ailments such as psoriasis, eczema, skin cancer and disorders associated with Type I diabetes. It may be used daily and left overnight, and may be applied sparingly over the affected area using an implement such as a cotton bud.</p>
<p>The oils of the invention range in colour and consistency depending on ozone concentration and temperature; they may take on a solid form with a creamy consistency or may be a viscous oil.</p>
<p>The oils may be used per Se, without any excipients. If desired, however, other cosmetically or pharmaceutically acceptable ingredients may be included in the formulations, such as aromatic essential oils to mask the odour of ozone.</p>
<p>Example I -Measurement of the effect of the ozonated oils of the invention on the oxygen supply in the skin Measurements of skin oxygen saturation (SO2) are carried out using a Whitland Research RM200 tissue SO2 monitor using two probes with different catchment depths: one which measures predominantly in the capillaries of the subpapilary plexus, the other which encompasses the venous plexus and some vessels of the deep dermal plexus.</p>
<p>Healthy human volunteers without a Latex allergy are accimatised at ambient 23 C for 15 minutes, and 3 sites of area approximately 1 cm2 are chosen on the right cheeks of the subjects and a fourth site on the left. The sites are chosen to avoid any visible veins, blemishes or pigmentations, and are marked discretely so that the same sites can be located for the subsequent measurements. Initial, baseline measurements with both probes are carried out at all four sites. On each occasion, approximately 10 measurements are made over the area of each site.</p>
<p>An ozonated oil of the invention is then applied by gentle massage to the first test site on the right cheek. The same oil, but not containing ozone, is similarly applied to the second site on the right cheek. The third site on the right cheek and the fourth site on the left cheek is similarly massaged, but without the application of any oil (both are considered as control sites, one on each sidc). Subsequent measurements are carried out at all 4 sites using the 2 probes at 30 minutes, 1 hour, 6 hours and 24 hours following application of the oils.</p>
<p>Results are analysed using the mean SO2 values measured at each site, treating the results from the 2 probes separately, and appropriate statistical techniques are applied.</p>
<p>Example 2 -Treatment of dyshidrotic eczema In the course of treating a female with dyshidrotic eczema, avocado oil ozonated to a concentration of 2.61 % was applied to her hands twice daily, in the morning and at night. After some initial inflammation on the right hand, both hands healed completely after a relatively short period of time. Use of this serum thus allowed the condition to be stabilized and healing occurred at a greater healing rate than with previously used products.</p>
<p>Example 3 -Treatment of acne Candida is an opportunistic yeast that normally resides harmlessly in the digestive system. In the abnormal state, however, Candida proliferates and converts into an invasive form to spread from the intestinal tract into the blood stream. This is known as a systemic Candida infection. One of the many symptoms from Candida is severe acne that ranges from white heads, papule, pustules and nodules.</p>
<p>A female who had been suffering with Candidasis for two years had all four symptoms of acne mentioned above. The healing rate of her skin was slow due to the life cycle of the nodules and papule, and her skin had very little time to recover due to new outbreaks that occurred regularly, especially when she menstruated.</p>
<p>She was given avocado oil ozonated to a concentration of 3.62 % to be massaged well into the affected areas for 10 minutes every night, and left to be absorbed overnight. In just under one month the outbreaks had begun to slow down, the redness had decreased by 70% and the purple colourisation had completely disappeared. The nodules had shrunk by 50%, the pain, itchiness and irritation had disappeared and only papule acne was coming out through the skin, decreased by 70%. With continued treatment the skin started to become soft and showed signs of smoothness. Subsequent new outbreaks, correlating with the timing of the patient's menstrual cycle, were less severe than previously experienced and began to heal at an accelerated rate, within a matter of days.</p>
<p>Example 4 -Treatment of acne A female presented a severe spread of acne (white heads and papules) around both shoulders and back. Previously used cleansing products and acne creams had had an effect but had not stopped the continuation of outbreaks of the spots. The papule spots cycle lasted a month before they disappeared.</p>
<p>Her treatment plan involved cleansing the affected areas with warm water and exfoliant, followed by application of sparing amounts of the serum directly onto the skin and massage with pressure for 20 -25 minutes until a warming heat was produced, twice per week.</p>
<p>Two days after the first treatment, the soreness and pain was no longer present.</p>
<p>Just before the third treatment the skin was soft and smooth in all the affected areas; all papules had been eliminated with no reoccurrence since the second treatment and all white heads have been eliminated apart from two fresh ones on the shoulders. After the third treatment, there was no reoccurrence of white heads or papules on the affected areas, and the skin remained bright, vibrant, smooth and soft. -11 -</p>
<p>The serum provided a superior healing rate and effective treatment for acne. It continued to work after each treatment due the ozonides that were stored at a cellular level to continue the healing process in between each of the treatment sessions.</p>
Claims (4)
- <p>Claims 1. A pharmaceutically or cosmetically acceptable oil that hasbeen ozonated with an amount of ozone less than the amount required to saturate the oil.</p><p>2. An oil according to claim 1, that has been ozonated with 10-70 % preferably 30 -50 %, of the amount of ozone required to saturate the oil.</p><p>3. An oil according to claim 1 or 2, containing unsaturated compounds, preferably unsaturated fatty acids.</p><p>4. An oil according to claim 3, containing a higher concentration of long chain fatty acids relative to short chain fatty acids.</p><p>5. An oil according to any of the preceding claims, wherein at least part of the ozone reacts with the oil, preferably to form lipoperoxides, ozonides or aldehydes.</p><p>6. An oil according to any of the preceding claims, comprising ozone in unreacted form, in sequestered form or as a clathrate.</p><p>7. An oil according to any of the preceding claims, containing at least one antioxidant, preferably vitamin E. 8. An oil according to any of the preceding claims, comprising ozonated compounds capable of passage through to the intercellular space of red blood cells and immunocompetent cells upon application of said oil to the skin.</p><p>9. An oil according to any of the preceding claims, which releases or causes the generation of active oxygen species, preferably free radicals or hydroxyl radicals, upon application to the skin.</p><p>10. An oil according to any of the preceding claims, which traps free radicals or suppresses their generation in vivo.</p><p>11. An ozonated avocado oil according to any of the preceding claims.</p><p>12. Avocado oil ozonated with 1.0 -6.0 g of ozone per 100 g of oil.</p><p>13. Ozonated avocado oil containing 1.0-6.0 % ozonated compounds.</p><p>14. A pharmaceutically or cosmetically acceptable formulation comprising an oil according to any of the preceding claims, for topical application to the skin.</p><p>15. A formulation according to claim 14, for delivery of ozonated compounds primarily to the epidermis.</p><p>16. A formulation according to claim 14, for delivery of ozonated compounds primarily to the epidermis and papillary dermis.</p><p>17. A formulation according to claim 14, for delivery of ozonated compounds to the epidermis, papillary dermis and reticular dermis, but not to adipose tissue.</p><p>18. A cosmetic formulation according to any of claims 14 to 17.</p><p>19. A lip balm, moisturiser, facial, cleanser or anti-aging product, or massage oil comprising a formulation according to claim 14.</p><p>20. A lip balm according to claim 19, containing 1.0-2.0%, preferably 1.5-1.9 %, preferably 1.72 % ozonated compounds.</p><p>21. A moisturiser according to claim 19, containing
- 2.0 -3.0 %, preferably 2.3 - 2.8 % preferably 2.59 % ozonated compounds.</p><p>22. A facial, cleanser or anti-aging product according to claim 19, containing
- 3.0 -4.0 % preferably 3.4 -3.8 % preferably 3.61 % ozonated compounds.</p><p>23. A massage oil according to claim 19, containing
- 4.0 -5.0 %, preferably 4.3 - 4.7 % preferably 4.50 % ozonated compounds.</p><p>24. Use of a formulation according to claim 14 as a lip balm, moisturiser, facial, cleanser or anti-aging product, or as a massage oil.</p><p>25. An oil according to any of claims I to 13 for use in therapy.</p><p>26. Use of an oil according to any of claims 1 to 13 for the manufacture of a medicament for use in the treatment or prophylaxis of a dermatological condition, disease or disorder.</p><p>27. Use according to claim 26 for the manufacture of a medicament for use in the treatment or prophylaxis of acne, psoriasis, eczema, skin cancer or a dermatological condition, disease or disorder associated with Type I diabetes.</p>
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2007/050654 WO2008050157A2 (en) | 2006-10-24 | 2007-10-24 | Ozonated oil formulations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0521873.0A GB0521873D0 (en) | 2005-10-27 | 2005-10-27 | Pure 03 serums |
Publications (3)
Publication Number | Publication Date |
---|---|
GB0621173D0 GB0621173D0 (en) | 2006-12-06 |
GB2431581A true GB2431581A (en) | 2007-05-02 |
GB2431581A8 GB2431581A8 (en) | 2010-03-03 |
Family
ID=35515790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0521873.0A Ceased GB0521873D0 (en) | 2005-10-27 | 2005-10-27 | Pure 03 serums |
GB0621173A Withdrawn GB2431581A (en) | 2005-10-27 | 2006-10-24 | Ozonated oil formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0521873.0A Ceased GB0521873D0 (en) | 2005-10-27 | 2005-10-27 | Pure 03 serums |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB0521873D0 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20110354A1 (en) * | 2011-03-07 | 2012-09-08 | Neovalis S R L | COMPOSITION BASED ON OZONIZED OIL FOR TOPICAL USE |
WO2013040721A1 (en) * | 2011-08-10 | 2013-03-28 | Hernandez Pavez Jose Octavio | Method and system for producing ozonated natural oils and the application thereof in the treatment of humans, animals and vegetables, and in aquaculture |
ITUB20155250A1 (en) * | 2015-11-24 | 2017-05-24 | Apuzzo Dario | New nutraceutical composition, orally administered, useful for exercising a powerful stimulation of the metabolism, in particular of the muscular energy metabolism. |
ITUB20156007A1 (en) * | 2015-11-30 | 2017-05-30 | S I P R E S S R L | PROCEDURE FOR THE PRODUCTION OF OZONIZED NATURAL OILS AND OZONIZED NATURAL OIL MADE WITH THIS PROCEDURE |
IT201600078872A1 (en) * | 2016-07-27 | 2018-01-27 | Fb Vision S R L | OIL AND DEVICE FOR HYGIENE OF THE EYE AND PERIOCULAR AREA |
IT201600111171A1 (en) * | 2016-11-04 | 2018-05-04 | Uras Cosmetics S R L S | KIT FOR SKIN TREATMENT AND ITS USE |
EP3506876B1 (en) * | 2016-08-31 | 2021-03-03 | Unigroup ApS | Composition for nail fungus |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040108402A (en) * | 2003-06-17 | 2004-12-24 | 주식회사 아이이아이 | A Cosmetic including the oil of o·zone oxide |
US20050113441A1 (en) * | 1999-11-25 | 2005-05-26 | Moraleda Manuel-Antonia G. | Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields |
WO2006021924A1 (en) * | 2004-08-26 | 2006-03-02 | Pieter Josua Le Roux | Therapeutic oil from plant origine |
US20060074129A1 (en) * | 2002-04-08 | 2006-04-06 | Mirabal Jesus M | Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes |
US20060153939A1 (en) * | 2003-02-14 | 2006-07-13 | Ordonez Jacome Neptali R C | Method of obtaining and treating compounds from ozonized unsaturated vegetable oils for pharmaceutical compositions for medical and veterinary use |
-
2005
- 2005-10-27 GB GBGB0521873.0A patent/GB0521873D0/en not_active Ceased
-
2006
- 2006-10-24 GB GB0621173A patent/GB2431581A/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050113441A1 (en) * | 1999-11-25 | 2005-05-26 | Moraleda Manuel-Antonia G. | Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields |
US20060074129A1 (en) * | 2002-04-08 | 2006-04-06 | Mirabal Jesus M | Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes |
US20060153939A1 (en) * | 2003-02-14 | 2006-07-13 | Ordonez Jacome Neptali R C | Method of obtaining and treating compounds from ozonized unsaturated vegetable oils for pharmaceutical compositions for medical and veterinary use |
KR20040108402A (en) * | 2003-06-17 | 2004-12-24 | 주식회사 아이이아이 | A Cosmetic including the oil of o·zone oxide |
WO2006021924A1 (en) * | 2004-08-26 | 2006-03-02 | Pieter Josua Le Roux | Therapeutic oil from plant origine |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20110354A1 (en) * | 2011-03-07 | 2012-09-08 | Neovalis S R L | COMPOSITION BASED ON OZONIZED OIL FOR TOPICAL USE |
WO2012120454A1 (en) * | 2011-03-07 | 2012-09-13 | Neovalis S.R.L. | Composition for topical use based on ozonized oil |
WO2013040721A1 (en) * | 2011-08-10 | 2013-03-28 | Hernandez Pavez Jose Octavio | Method and system for producing ozonated natural oils and the application thereof in the treatment of humans, animals and vegetables, and in aquaculture |
ITUB20155250A1 (en) * | 2015-11-24 | 2017-05-24 | Apuzzo Dario | New nutraceutical composition, orally administered, useful for exercising a powerful stimulation of the metabolism, in particular of the muscular energy metabolism. |
ITUB20156007A1 (en) * | 2015-11-30 | 2017-05-30 | S I P R E S S R L | PROCEDURE FOR THE PRODUCTION OF OZONIZED NATURAL OILS AND OZONIZED NATURAL OIL MADE WITH THIS PROCEDURE |
IT201600078872A1 (en) * | 2016-07-27 | 2018-01-27 | Fb Vision S R L | OIL AND DEVICE FOR HYGIENE OF THE EYE AND PERIOCULAR AREA |
WO2018020456A1 (en) * | 2016-07-27 | 2018-02-01 | Fb Vision S.R.L. | Oil and device for cleaning the ocular and periocular area |
EP3506876B1 (en) * | 2016-08-31 | 2021-03-03 | Unigroup ApS | Composition for nail fungus |
IT201600111171A1 (en) * | 2016-11-04 | 2018-05-04 | Uras Cosmetics S R L S | KIT FOR SKIN TREATMENT AND ITS USE |
Also Published As
Publication number | Publication date |
---|---|
GB0621173D0 (en) | 2006-12-06 |
GB2431581A8 (en) | 2010-03-03 |
GB0521873D0 (en) | 2005-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100928211B1 (en) | Compositions for the treatment of sun damage and compositions for reducing acne lesions | |
US8008345B2 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
GB2431581A (en) | Ozonated oil formulations | |
KR100673044B1 (en) | The composition for external use by percutaneous administration | |
US9579274B2 (en) | Vitamin C composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same | |
WO2008050157A2 (en) | Ozonated oil formulations | |
CN115429738B (en) | Acne-removing, repairing and reviving essence and preparation method thereof | |
WO2002058640A1 (en) | Topical therapeutic skin care system | |
Draelos et al. | The effect of vehicle formulation on acne medication tolerability | |
US20180325973A1 (en) | Skin care composition | |
EP3378474B1 (en) | Composition for the use in the treatment of plantar hyperhidrosis predisposing to cutaneous fungal infection of the foot | |
CN112791093A (en) | Transdermal drug delivery composition for treating acne and preparation method thereof | |
CN112402309A (en) | Multi-vitamin mineral essence cream and preparation method thereof | |
US20210052524A1 (en) | N-acetylcysteine and urea-based formulation for the treatment of dermatological disorders | |
RU2283642C1 (en) | Anti-cellulitis cream | |
WO2007133641A1 (en) | Enhanced protection against skin injury in humans | |
Chernoff | A novel combination therapy in aesthetic and reconstructive surgery: sea salt, exfoliation, cavitating ultrasound, and high intensity multiwavelength LED treatment:(SaltFacial) | |
EP4085913A1 (en) | Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea | |
US8969411B2 (en) | Vitamin C composition for use in the prevention and treatment of stretch other skin conditions and methods of using the same | |
RU2780260C1 (en) | Cosmetic for skin | |
WO2018041319A1 (en) | Composition for nail fungus | |
WO2009020398A2 (en) | Skin care product | |
Mirodilova et al. | OPTIMIZATION OF THE TREATMENT OF PATHOLOGICAL DRYNESS OF THE SKIN | |
AU2023203452B1 (en) | Topical formulations | |
RU2577297C1 (en) | Method for outpatient treatment of facial skin of patients with rosacea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |